Regulation at every stage of a product’s life cycle, enormous multi-district litigation—these are only a couple of challenges for Legal Division leaders at one of the world’s largest pharmaceutical companies. LMG Life Sciences Editor Kevin Matha discussed these matters with Ellen Rosenthal (pictured, right), Chief Counsel of the Pfizer Legal Alliance, to learn more about the company’s groundbreaking program to control costs and build a better client-attorney relationship.
Many life sciences attorneys act as an outside general counsel for venture capital and start-up companies. But a number of venture capital firms have recently created general counsel positions. LMG Life Sciences Editor Kevin Matha discussed the trend with Hooman Shahlavi, General Counsel at Sofinnova Ventures – a venture capital firm starting its eighth fund which focuses solely on life sciences.
The life sciences industry deals with a cavalcade of legal issues. So when it comes to deciding what law firm to help them navigate the maze of the market, adding more headaches isn’t at the top of their priority list. LMG Life Sciences Head Writer Philip Bausk talked to a few attorneys about how they are billing their clients.
Cameron Findlay was appointed General Counsel of Medtronic in 2009 and has embarked on a new strategy to rein in legal costs at one of world’s largest medical device manufacturers. LMG Life Sciences Editor Kevin Matha reports on how a company with over $15 billion in revenue is trying to do just that.
Sweeping new patent legislation in the form of the American Invents Act (AIA) has the life sciences industry buzzing. LMG Life Sciences Editor Kevin Matha spoke with Robert A. Armitage (pictured), Senior Vice President and General Counsel at Eli Lilly and Company, about the new legislative package.
In the ever-changing life sciences industry, it is rare to find professionals who have seen the dramatic shifts within the industry over the last few decades. Both Tom Ciotti and Kate Murashige have been heavily involved in patent law for nearly five decades and are familiar with the swings the industry has seen both from a legal and a technological perspective. LMG Life Sciences Head Writer Phillip Bausk spoke with Ciotti and Murashige about their experiences working in life sciences.
CMS formalizes its Medicare Part D Coverage Gap Discount Program rules as part of an omnibus Medicare Part C and Part D rulemaking. By Andrew Ruskin and Donna Lee Yesner of Morgan, Lewis & Bockius LLP.
By Stephen Paul Mahinka and Kathleen M. Sanzo of Morgan, Lewis & Bockius.
By Ha Kung Wong and John Kirkland of FItzpatrick, Cella, Harper & Scinto.
The life sciences industry faces greater scrutiny from government regulators, putting enormous pressure on companies to comply. LMG Life Sciences Editor Kevin Matha discussed that issue and more with Raymond Bonner (pictured, below), who has dedicated his practice to handling some of the industry’s toughest problems.
Very sorry to hear this.
Wubbo received an outstanding achievement award from Managing IP in 2009… https://t.co/bz7via7FGz
Rethinking the funding of biomedical research doesn't have to be an attack on patents - @jamie_love at #fordhamip p… https://t.co/gmGDFsX7NA
.@davidangusstone has prompted a very lively discussion on designs v trademarks v copyright. #fordhamip #fashionlaw https://t.co/AjDt8UNbkB
Patent subject matter eligibility: A new Section 101
Calls for changing Section 101 of the Patent Act in the US are increasing. A proposed amendment from IPO shows one way to do it, reports Michael Loney
The material on this site is for financial institutions, professional investors
and their professional advisers. It is for information only. Please read our
Terms and Conditions
before using the site. All material subject to strictly enforced copyright laws.
© 2017 Euromoney Institutional Investor PLC. For help please
see our FAQ.
Switching to MIP International